var data={"title":"Fludarabine: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Fludarabine: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6205?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=fludarabine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Fludarabine: Patient drug information&quot;</a> and <a href=\"topic.htm?path=fludarabine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Fludarabine: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708775\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Bone marrow suppression:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Fludarabine can severely suppress bone marrow function.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Autoimmune effects:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Instances of life-threatening and sometimes fatal autoimmune phenomena, such as hemolytic anemia, autoimmune thrombocytopenia/thrombocytopenic purpura, Evans syndrome, and acquired hemophilia, have been reported to occur after 1 or more cycles of treatment with fludarabine. Patients undergoing treatment with fludarabine should be evaluated and closely monitored for hemolysis.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Neurotoxicity:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">When used at high doses in dose-ranging studies in patients with acute leukemia, fludarabine was associated with severe neurologic effects, including blindness, coma, and death. This severe CNS toxicity occurred in 36% of patients treated with dosages approximately 4 times greater (96 mg/m<sup>2</sup>/day for 5 to 7 days) than the recommended dosage. Similar severe CNS toxicity, including agitation, coma, confusion, and seizures, has been reported (0.2% or less) in patients treated at doses in the range of the dose recommended for chronic lymphocytic leukemia.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Combination with pentostatin:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">In a clinical investigation using fludarabine in combination with pentostatin (deoxycoformycin) for the treatment of refractory chronic lymphocytic leukemia, there was an unacceptably high incidence of fatal pulmonary toxicity. Therefore, the use of fludarabine in combination with pentostatin is not recommended.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Experienced physician:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Fludarabine injection should be administered under the supervision of a qualified health care provider experienced in the use of antineoplastic therapy.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171868\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Fludara [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171869\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Fludara;</li>\n      <li>Fludarabine Phosphate for Injection;</li>\n      <li>Fludarabine Phosphate for Injection, USP;</li>\n      <li>Fludarabine Phosphate Injection, PPC STD.</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171908\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antineoplastic Agent, Antimetabolite;</li>\n      <li>\n        Antineoplastic Agent, Antimetabolite (Purine Analog)</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171872\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic lymphocytic leukemia (CLL), refractory or progressive:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: 25 mg/m<sup>2</sup> once daily for 5 consecutive days every 28 days; continue for at least 3 additional cycles after maximal response is achieved</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral (Canadian product; not available in US): 40 mg/m<sup>2</sup> once daily for 5 consecutive days every 28 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>CLL combination regimens (off-label dosing):</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">FC regimen: 30 mg/m<sup>2</sup>/day for 3 days every 28 days for 6 cycles (in combination with cyclophosphamide) (Eichhorst 2006) <b>or</b> 20 mg/m<sup>2</sup>/day for 5 days every 28 days for 6 cycles (in combination with cyclophosphamide) (Flinn 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">FCR regimen: 25 mg/m<sup>2</sup>/day for 3 days every 28 days for 6 cycles (in combination with cyclophosphamide and rituximab) (Keating 2005; Robak 2010; Wierda 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">FR regimen: 25 mg/m<sup>2</sup>/day for 5 days every 28 days for 6 cycles (in combination with rituximab) (Byrd 2003)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">OFAR regimen: 30 mg/m<sup>2</sup>/day for 2 days every 28 days for 6 cycles (in combination with oxaliplatin, cytarabine, and rituximab) (Tsimberidou 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute myeloid leukemia, newly diagnosed (off-label use): </b>IV: 30 mg/m<sup>2</sup>/day for 5 days (in combination with cytarabine &plusmn; G-CSF &plusmn; idarubicin (FA, FLAG, or FLAG-IDA regimens), followed by consolidation therapy (Borthakur 2008; Burnett 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute myeloid leukemia, refractory or high/poor-risk patients (off-label use):</b> IV: 30 mg/m<sup>2</sup>/day for 5 days (in combination with cytarabine and filgrastim [FLAG regimen]), may repeat once for partial remission (Montillo 1998) <b>or</b> 30 mg/m<sup>2</sup>/day for 5 days for 1 or 2 cycles (in combination with cytarabine, idarubicin, and filgrastim FLAG-IDA regimen]) (Virchis 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hematopoietic stem cell transplant (allogeneic) myeloablative conditioning regimen (off-label use):</b> IV: 40 mg/m<sup>2</sup>/day for 4 days (in combination with busulfan) beginning 6 days prior to transplantation (Rambaldi 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hematopoietic stem cell transplant (allogeneic) reduced-intensity conditioning regimen (off-label use):</b> IV: 30 mg/m<sup>2</sup>/day for 5 days (in combination with melphalan and alemtuzumab) prior to transplant (Tauro 2005) <b>or</b> 30 mg/m<sup>2</sup>/day for 6 days beginning 10 days prior to transplant <b>or</b> 30 mg/m<sup>2</sup>/day for 5 days beginning 6 days prior to transplant (in combination with busulfan with or without antithymocyte globulin) (Schetelig 2003)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hematopoietic stem cell transplant (allogeneic) nonmyeloablative conditioning regimen (off-label use):</b> IV: 30 mg/m<sup>2</sup>/day for 3 doses beginning 5 days prior to transplant (in combination with cyclophosphamide and rituximab) (Khouri 2008) <b>or</b> 30 mg/m<sup>2</sup>/day for 3 doses beginning 4 days prior to transplant (in combination with total body irradiation) (Hegenbart 2006; Rezvani 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Non-Hodgkin lymphomas (off-label use):</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Follicular lymphoma, relapsed/refractory</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">FCR regimen: 25 mg/m<sup>2</sup>/day for 3 days every 21 days for 4 cycles (in combination with cyclophosphamide and rituximab) (Sacchi 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">FCMR regimen: 25 mg/m<sup>2</sup>/day for 3 days every 28 days for 4 cycles (in combination with cyclophosphamide, mitoxantrone, and rituximab) (Forstpointner 2004; Forstpointner 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">FNDR regimen: 25 mg/m<sup>2</sup>/day for 3 days every 28 days for up to 8 cycles (in combination with mitoxantrone, dexamethasone, and rituximab) (McLaughlin 2000)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">FR regimen: 25 mg/m<sup>2</sup>/day for 5 days every 28 days for 6 cycles (in combination with rituximab) (Czuczman 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mantle cell lymphoma, relapsed or refractory:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">FC regimen: 20 mg/m<sup>2</sup>/day for 4 to 5 days or 25 mg/m<sup>2</sup>/day for 3 to 5 days (in combination with cyclophosphamide) (Cohen 2001)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Waldenstrom macroglobulinemia (off-label use):</b> IV: 25 mg/m<sup>2</sup>/day for 5 days every 28 days (Foran 1999) <b>or</b> 25 mg/m<sup>2</sup> once daily for 5 days during weeks 5, 9, 13, 19, 23, and 27 (in combination with rituximab) (Treon 2009)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171891\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=fludarabine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Fludarabine: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute lymphocytic leukemia, relapsed (off-label use):</b> IV: 10.5 mg/m<sup>2</sup> bolus over 15 minutes followed by a continuous infusion of 30.5 mg/m<sup>2</sup>/day for 48 hours in combination with cytarabine (Avramis 1998). Additional studies may be necessary to further define the role of fludarabine in the condition.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute myeloid leukemia, newly diagnosed (off-label use):</b> IV: 10.5 mg/m<sup>2</sup> bolus infusion followed by a continuous infusion of 30.5 mg/m<sup>2</sup>/day for 48 hours (in combination with cytarabine and idarubicin) during consolidation phase of treatment (Lange 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute myeloid leukemia, relapsed (off-label use):</b> IV: 10.5 mg/m<sup>2</sup> bolus over 15 minutes followed by a continuous infusion of 30.5 mg/m<sup>2</sup>/day for 48 hours in combination with cytarabine (Avramis 1998). Additional studies may be necessary to further define the role of fludarabine in the condition.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hematopoietic stem cell transplant (allogeneic), reduced-intensity conditioning regimen (off-label use):</b> IV: 30 mg/m<sup>2</sup> once daily for 6 doses beginning 7 to 10 days prior to transplant (in combination with busulfan and antithymocyte globulin [rabbit]) (Pulsipher 2009)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171873\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171874\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adults: CLL:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &ge;80 mL/minute: No dosage adjustment necessary (administer the usual dose of 25 mg/m<sup>2</sup>).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 50 to 79 mL/minute: Reduce dose to 20 mg/m<sup>2</sup>.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 30 to 49 mL/minute: Reduce dose to 15 mg/m<sup>2</sup>.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &lt;30 mL/minute: Use is not recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral (Canadian product; not available in US):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 30 to 70 mL/minute: Reduce dose by up to 50%.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &lt;30 mL/minute: Use is contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">The following adjustments have also been used: Aronoff 2007: IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 10 to 50 mL/minute: Reduce dose to 75% of usual dose.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &lt;10 mL/minute: Reduce dose to 50% of usual dose.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hemodialysis: Reduce dose to 50% of usual dose; administer after dialysis</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous ambulatory peritoneal dialysis (CAPD): Reduce dose to 50% of usual dose.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous renal replacement therapy (CRRT): Reduce dose to 75% of usual dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pediatrics:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 30 to 50 mL/minute: Reduce dose to 80% of usual dose.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &lt;30 mL/minute: Use is not recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hemodialysis: Reduce dose to 25% of usual dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous ambulatory peritoneal dialysis (CAPD): Use is not recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous renal replacement therapy (CRRT): Reduce dose to 80% of usual dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15881449\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20344391\" class=\"block doo drugH1Div\"><span class=\"drugH1\">Dosing: Obesity</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>American Society of Clinical Oncology (ASCO) Guidelines for appropriate chemotherapy dosing in obese adults with cancer (<b>Note:</b> Excludes leukemias and HSCT dosing):</i> Utilize patient's actual body weight (full weight) for calculation of body surface area- or weight-based dosing, particularly when the intent of therapy is curative; manage regimen-related toxicities in the same manner as for nonobese patients; if a dose reduction is utilized due to toxicity, consider resumption of full weight-based dosing with subsequent cycles, especially if cause of toxicity (eg, hepatic or renal impairment) is resolved (Griggs 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>American Society for Blood and Marrow Transplantation (ASBMT) practice guideline committee position statement on chemotherapy dosing in obesity:</i> Utilize actual body weight (full weight) for calculation of body surface area in fludarabine dosing for hematopoietic stem cell transplant conditioning regimens in adults (Bubalo 2014).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6853864\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic or nonhematologic toxicity (other than neurotoxicity): Consider treatment delay or dosage reduction.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hemolysis: Discontinue treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neurotoxicity: Consider treatment delay or discontinuation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171848\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous, as phosphate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg/2 mL (2 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous, as phosphate [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg/2 mL (2 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous, as phosphate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Fludara: 50 mg (1 ea [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous, as phosphate [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171833\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5950041\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet, as phosphate:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Fludara: 10 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171851\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: The manufacturer recommends administering over ~30 minutes (for the treatment of CLL). Continuous infusions and IV bolus over 15 minutes have been used for some off-label protocols (refer to individual studies for infusion rate details).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Tablet [Canadian product] may be administered with or without food; should be swallowed whole with water; do not chew, break, or crush.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49132595\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 1]).   </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends double gloving, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and closed system transfer devices (CSTDs) for preparation. Double gloving, a gown, and (if dosage form allows) CSTDs are required during administration. In regions where an oral dosage form is available, NIOSH recommends single gloving for administration of intact tablets/capsules (NIOSH 2016).   </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171849\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Chronic lymphocytic leukemia (refractory or progressive):</b> Treatment of B-cell chronic lymphocytic leukemia (CLL) in adults who have not responded to or have progressed during treatment with at least one standard regimen containing an alkylating agent.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25725592\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Acute myeloid leukemia (adults) (newly diagnosed); Acute myeloid leukemia (adults) (refractory or high/poor risk); Acute lymphocytic leukemia (pediatric) (relapsed); Acute myeloid leukemia (pediatrics) (newly diagnosed); Acute myeloid leukemia (pediatric) (relapsed); Hematopoietic stem cell transplant (allogeneic) myeloablative conditioning regimen (older adults); Hematopoietic stem cell transplant (allogeneic) nonmyeloablative conditioning regimen (adults); Hematopoietic stem cell transplant (allogeneic) reduced-intensity conditioning regimen (adults); Hematopoietic stem cell transplantation (allogeneic) reduced-intensity conditioning regimen (pediatrics); Non-Hodgkin lymphoma: Follicular lymphoma (relapsed/refractory); Non-Hodgkin lymphoma: Mantle cell lymphoma (relapsed/refractory); Waldenstr&ouml;m macroglobulinemia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171916\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Fludarabine may be confused with cladribine, floxuridine, flucytosine, Flumadine</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Fludara may be confused with FUDR</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171840\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not always defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Edema (8% to 19%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Fatigue (10% to 38%), neurological signs and symptoms (doses &gt;96 mg/m<sup>2</sup> /day for 5 to 7 days: 36%; doses &lt;125 mg/m<sup>2</sup>/cycle: &lt;1%; characterized by cortical blindness, coma, and paralysis; symptom onset may be delayed for 3 to 4 weeks), pain (20% to 22%), chills (11% to 19%), paresthesia (4% to 12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (15%), diaphoresis (1% to 13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea and vomiting (31% to 36%), anorexia (7% to 34%), diarrhea (13% to 15%), gastrointestinal hemorrhage (3% to 13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary tract infection (2% to 15%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Anemia (60%), neutropenia (grade 4: 59%; nadir: ~13 days), thrombocytopenia (55%; nadir: ~16 days), bone marrow depression (nadir: 10 to 14 days; recovery: 5 to 7 weeks; dose-limiting toxicity)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Infection (33% to 44%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Weakness (9% to 65%), myalgia (4% to 16%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Visual disturbance (3% to 15%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Cough (10% to 44%), pneumonia (16% to 22%), dyspnea (9% to 22%), upper respiratory tract infection (2% to 16%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (60% to 69%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Angina pectoris (&le;6%), cardiac arrhythmia (&le;3%), cardiac failure (&le;3%), cerebrovascular accident (&le;3%), myocardial infarction (&le;3%), supraventricular tachycardia (&le;3%), deep vein thrombosis (1% to 3%), phlebitis (1% to 3%), aneurysm (&le;1%), transient ischemic attacks (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Malaise (6% to 8%), headache (&le;3%), sleep disorder (1% to 3%), cerebellar syndrome (&le;1%), depression (&le;1%), difficulty thinking (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Alopecia (&le;3%), pruritus (1% to 3%), seborrhea (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hyperglycemia (1% to 6%), dehydration (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Stomatitis (&le;9%), cholelithiasis (&le;3%), esophagitis (&le;3%), constipation (1% to 3%), mucositis (&le;2%), dysphagia (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Dysuria (3% to 4%), urinary hesitancy (&le;3%), hematuria (2% to 3%), proteinuria (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Hemorrhage (&le;1%), tumor lysis syndrome (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Abnormal hepatic function tests (1% to 3%), hepatic failure (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Anaphylaxis (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Osteoporosis (&le;2%), arthralgia (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Otic: Hearing loss (2% to 6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Renal failure (&le;1%), renal function test abnormality (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Pharyngitis (&le;9%), hypersensitivity pneumonitis (&le;6%), hemoptysis (1% to 6%), sinusitis (&le;5%), bronchitis (&le;1%), epistaxis (&le;1%), hypoxia (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Acquired blood coagulation disorder, acute myelocytic leukemia (usually associated with prior or concurrent treatment with other anticancer agents), adult respiratory distress syndrome, agitation, autoimmune hemolytic anemia, autoimmune thrombocytopenia, blindness, bone marrow aplasia (trilineage), bone marrow depression (trilineage), cerebral hemorrhage, coma, confusion, Epstein-Barr-associated lymphoproliferative disorder, erythema multiforme, Evans syndrome, flank pain, hemorrhagic cystitis, herpes zoster (reactivation), hyperkalemia, hyperphosphatemia, hyperuricemia, hypocalcemia, immune thrombocytopenia (autoimmune), increased liver enzymes, interstitial pneumonitis, malignant neoplasm of skin (new-onset or exacerbation), metabolic acidosis, myelodysplastic syndrome (usually associated with prior or concurrent treatment with other anticancer agents), myelofibrosis, opportunistic infection, optic neuritis, optic neuropathy, pancreatic disease (pancreatic enzymes abnormal), pancytopenia, pemphigus, pericardial effusion, peripheral neuropathy, pneumonitis, progressive multifocal leukoencephalopathy (PML), pulmonary fibrosis, pulmonary hemorrhage, reactivation of latent Epstein-Barr virus, respiratory distress, respiratory failure, seizure, Stevens-Johnson syndrome, toxic epidermal necrolysis, urate crystalluria, wrist-drop</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171854\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">There are no contraindications listed in the manufacturer's US labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling: </i>Hypersensitivity to fludarabine or any component of the formulation; severe renal impairment (CrCl &lt;30 mL/minute); decompensated hemolytic anemia; concurrent use with pentostatin</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171837\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Autoimmune effects: <b>[US Boxed Warning]: Life-threatening (and sometimes fatal) autoimmune effects, including hemolytic anemia, autoimmune thrombocytopenia/thrombocytopenic purpura (ITP), Evans syndrome, and acquired hemophilia have occurred; evaluate and monitor closely for hemolysis.</b> This has occurred in patients with and without a history of autoimmune hemolytic anemia or a positive Coombs test, and who may or may not be in remission from their disease. Corticosteroids may or may not effectively control the hemolytic episodes. Discontinue fludarabine if hemolysis occurs. The hemolytic effects recurred in most patients when rechallenged with fludarabine.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone marrow suppression: <b>[US Boxed Warning]: Severe bone marrow suppression (anemia, thrombocytopenia, and neutropenia) may occur;</b> may be cumulative. The median time to nadir was 13 days (range: 3 to 25 days) for granulocytes and 16 days (range: 2 to 32 days) for platelets. Severe myelosuppression (trilineage bone marrow hypoplasia/aplasia) has been reported (rare) with a duration of significant cytopenias ranging from 2 months to 1 year. First-line combination therapy is associated with prolonged cytopenias, with anemia lasting up to 7 months, neutropenia up to 9 months, and thrombocytopenia up to 10 months; increased age is predictive for prolonged cytopenias (Gill 2010). Monitor patients with bone marrow impairment closely for excess toxicity; may require dosage reductions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infection: Serious and sometimes fatal infections, including opportunistic infections and reactivations of latent viral infections such as VZV (herpes zoster) and Epstein-Barr virus have been reported with fludarabine. Prophylactic anti-infectives should be considered for patients with an increased risk for developing opportunistic infections. Use with caution in patients with documented infection, fever, immunodeficiency, or with a history of opportunistic infection.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neurotoxicity:<b> [US Boxed Warning]: Higher than recommended doses (up to 96 mg/m<sup>2</sup>/day for 5 to 7 days) are associated with severe neurologic toxicity (delayed blindness, coma, death); similar neurotoxicity (agitation, coma, confusion, seizure) has been reported (rare) with standard CLL doses (25 mg/m<sup>2</sup>/day for 5 days).</b> Symptoms of neurotoxicity due to high doses appeared from 21 to 60 days following the last fludarabine dose, although neurotoxicity has been reported as early as 7 days and up to 225 days. Although administration of up to 15 courses of treatment have been used, the possible neurotoxic effects of chronic administration are unknown. Fatigue, weakness, visual disturbances, confusion, and seizures may occur; caution patients about performing tasks which require mental alertness (eg, operating machinery or driving).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Progressive multifocal leukoencephalopathy: Progressive multifocal leukoencephalopathy (PML) (usually fatal) due to JC virus has been reported; most cases were in patients who had received prior and/or other concurrent chemotherapy. Onset may be a few weeks or may be delayed up to 1 year. Evaluate any neurological change promptly.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Reproductive effects: Fludarabine may damage testicular tissue and spermatozoa.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Transfusion-associated graft-versus-host disease: Graft-versus-host disease (GVHD) has been observed following transfusion of non-irradiated blood in patients treated with fludarabine; fatal outcome has been observed. Patients receiving fludarabine should only receive irradiated blood products due to the potential for transfusion-related GVHD.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tumor lysis syndrome: May cause tumor lysis syndrome; risk is increased in patients with large tumor burden prior to treatment. Hydration and prophylactic antihyperuricemic therapy should be considered in patients at risk for tumor lysis syndrome.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; clearance of the primary metabolite 2-fluoro-ara-A is decreased in patients with renal impairment. Dosage reductions are recommended (monitor closely for excessive toxicity) in patients with creatinine clearance between 30 and 79 mL/minute; use is not recommended if CrCl &lt;30 mL/minute.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pentostatin: <b>[US Boxed Warning]: The use of fludarabine in combination with pentostatin (deoxycoformycin) for the treatment of refractory chronic lymphocytic leukemia has resulted in an unacceptably high incidence of fatal pulmonary toxicity. The use of fludarabine in combination with pentostatin is not recommended.</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Special populations:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Monitor closely for excessive toxicity; may require reduced doses.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Experienced physician:<b> [US Boxed Warning]: Should be administered under the supervision of an experienced cancer chemotherapy physician.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Live vaccines: Avoid vaccination with live vaccines during and after fludarabine treatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299343\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171842\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8452&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Imatinib: May diminish the myelosuppressive effect of Fludarabine. Imatinib may decrease the serum concentration of Fludarabine. More specifically, imatinib may decrease the formation of fludarabine active metabolite F-ara-ATP Management: Due to the risk for impaired fludarabine response, consider discontinuing imatinib therapy at least 5 days prior to initiating fludarabine conditioning therapy in CML patients undergoing HSCT.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim.  Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim.  Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentostatin: Fludarabine may enhance the adverse/toxic effect of Pentostatin. Pentostatin may enhance the adverse/toxic effect of Fludarabine. Pulmonary toxicity is of specific concern. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171844\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171856\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in animal reproduction studies. Based on the mechanism of action, fludarabine may cause fetal harm if administered during pregnancy. Effective contraception should be used to avoid pregnancy during and after treatment for women and men with female partners of reproductive potential.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5709863\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if fludarabine is present in breast milk. Due to the potential for serious adverse reactions in the breastfeeding infant, a decision should be made to discontinue breastfeeding or to discontinue fludarabine, taking into account the importance of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171846\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC with differential, platelet count, AST, ALT, serum creatinine, serum albumin, uric acid; monitor for signs of infection, neurotoxicity, and tumor lysis syndrome.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171836\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Fludarabine inhibits DNA synthesis by inhibition of DNA polymerase and ribonucleotide reductase; also inhibits DNA primase and DNA ligase I</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171853\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>ss</sub>: 11 to 96 L/m<sup>2</sup> (Johnson 2000)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 2-fluoro-ara-A: ~19% to 29%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: IV: Fludarabine phosphate is rapidly dephosphorylated in the plasma to 2-fluoro-ara-A (active metabolite), which subsequently enters tumor cells and is phosphorylated by deoxycytidine kinase to the active triphosphate derivative (2-fluoro-ara-ATP)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Oral: 2-fluoro-ara-A: 50% to 65%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: 2-fluoro-ara-A: Adults: ~20 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma: Oral: 1 to 2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (primarily) (Johnson 2000)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323155\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Fludarabine Phosphate Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (1): $132.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171857\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Beneflur (ES, MX);</li>\n      <li>Flucozol (EC);</li>\n      <li>Fludabin (UA);</li>\n      <li>Fludabine (LK);</li>\n      <li>Fludacel (PE);</li>\n      <li>Fludalym (VN);</li>\n      <li>Fludamin (BD);</li>\n      <li>Fludara (AT, AU, BE, BG, BH, CH, CL, CN, CO, CR, CY, CZ, DE, DK, DO, EE, FI, FR, GB, GR, GT, HK, HN, HR, HU, ID, IE, IL, IN, IS, IT, JO, JP, KR, KW, LB, LT, LU, LV, MT, MY, NI, NL, NO, NZ, PA, PH, PL, PY, QA, RO, RU, SA, SE, SG, SI, SK, SV, TH, TR, TW, UA, UY, VE, VN, ZA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 99, 172.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"9516951\"></a>Avramis VI, Wiersma S, Krailo MD, et al, &ldquo;Pharmacokinetic and Pharmacodynamic Studies of Fludarabine and Cytosine Arabinoside Administered as Loading Boluses Followed by Continuous Infusions After a Phase I/II Study in Pediatric Patients With Relapsed Leukemias. The Children's Cancer Group,&rdquo; <i>Clin Cancer Res</i>, 1998, 4(1):45-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fludarabine-drug-information/abstract-text/9516951/pubmed\" target=\"_blank\" id=\"9516951\">9516951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18932257\"></a>Borthakur G, Kantarjian H, Wang X, et al, &ldquo;Treatment of Core-Binding-Factor in Acute Myelogenous Leukemia With Fludarabine, Cytarabine, and Granulocyte Colony-Stimulating Factor Results in Improved Event-Free Survival,&rdquo; <i>Cancer</i>, 2008, 113(11):3181-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fludarabine-drug-information/abstract-text/18932257/pubmed\" target=\"_blank\" id=\"18932257\">18932257</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bubalo J, Carpenter PA, Majhail N, et al. Conditioning chemotherapy dose adjustment in obese patients: a review and position statement by the American Society for Blood and Marrow Transplantation practice guideline committee. <i>Biol Blood Marrow Transplant</i>. 2014;20(5):600-616.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fludarabine-drug-information/abstract-text/24462742/pubmed\" target=\"_blank\" id=\"24462742\">24462742</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23940227\"></a>Burnett AK, Russell NH, Hills RK, et al. Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial. <i>J Clin Oncol</i>. 2013;31(27):3360-3368. doi: 10.1200/JCO.2012.47.4874.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fludarabine-drug-information/abstract-text/23940227/pubmed\" target=\"_blank\" id=\"23940227\">23940227</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Byrd JC, Peterson BL, Morrison VA, et al, &ldquo;Randomized Phase 2 Study of Fludarabine With Concurrent vs Sequential Treatment With Rituximab in Symptomatic, Untreated Patients With B-Cell Chronic Lymphocytic Leukemia: Results From Cancer and Leukemia Group B 9712 (CALGB 9712),&rdquo; <i>Blood</i>, 2003, 101(1):6-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fludarabine-drug-information/abstract-text/12393429/pubmed\" target=\"_blank\" id=\"12393429\">12393429</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"11697618\"></a>Cohen BJ, Moskowitz C, Straus D, et al, &ldquo;Cyclophosphamide/Fludarabine (CF) is Active in the Treatment of Mantle Cell Lymphoma,&rdquo;  <i>Leuk Lymphoma</i>, 2001, 42(5):1015-22.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fludarabine-drug-information/abstract-text/11697618/pubmed\" target=\"_blank\" id=\"11697618\">11697618</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15681517\"></a>Czuczman MS, Koryzna A, Mohr A, et al, &ldquo;Rituximab in Combination With Fludarabine Chemotherapy in Low-Grade or Follicular Lymphoma,&rdquo; <i>J Clin Oncol</i>, 2005, 23(4):694-704.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fludarabine-drug-information/abstract-text/15681517/pubmed\" target=\"_blank\" id=\"15681517\">15681517</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Eichhorst BF, Busch R, Hopfinger G, et al, &ldquo;Fludarabine Plus Cyclophosphamide Versus Fludarabine Alone in First-Line Therapy of Younger Patients With Chronic Lymphocytic Leukemia,&rdquo; <i>Blood</i>, 2006, 107(3):885-891.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fludarabine-drug-information/abstract-text/16219797/pubmed\" target=\"_blank\" id=\"16219797\">16219797</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Flinn IW, Neuberg DS, Grever MR, et al, &ldquo;Phase III Trial of Fludarabine Plus Cyclophosphamide Compared With Fludarabine for Patients With Previously Untreated Chronic Lymphocytic Leukemia: US Intergroup Trial E2997,&rdquo; <i>J Clin Oncol</i>, 2007, 25(7):793-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fludarabine-drug-information/abstract-text/17283364/pubmed\" target=\"_blank\" id=\"17283364\">17283364</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fludara (fludarabine phosphate tablet) [product monograph]. Lavel, Quebec, Canada: Sanofi Aventis Canada Inc; September 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fludarabine phosphate injection [prescribing information]. Schaumberg, IL: Sagent Pharmaceuticals; August 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fludarabine phosphate injection [prescribing information]. North Wales, PA: Teva Pharmaceuticals USA; October 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fludarabine phosphate injection [prescribing information]. Schaumberg, IL: Sagent Pharmaceuticals; August 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fludarabine phosphate injection [product monograph]. Saint Laurent, Quebec, Canada: Hospira Healthcare Corporation; February 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"10080598\"></a>Foran JM, Rohatiner AZ, Coiffier B, et al, &ldquo;Multicenter Phase II Study of Fludarabine Phosphate for Patients With Newly Diagnosed Lymphoplasmacytoid Lymphoma, Waldenstr&ouml;m's Macroglobulinemia, and Mantle-Cell Lymphoma,&rdquo; <i>J Clin Oncol</i>, 1999, 17(2):546-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fludarabine-drug-information/abstract-text/10080598/pubmed\" target=\"_blank\" id=\"10080598\">10080598</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15284112\"></a>Forstpointner R, Dreyling M, Repp R, et al, &ldquo;The Addition of Rituximab to a Combination of Fludarabine, Cyclophosphamide, Mitoxantrone (FCM) Significantly Increases the Response Rate and Prolongs Survival as Compared With FCM Alone in Patients With Relapsed and Refractory Follicular and Mantle Cell Lymphomas: Results of a Prospective Randomized Study of the German Low-Grade Lymphoma Study Group,&rdquo; <i>Blood,</i> 2004, 104(10):3064-71.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fludarabine-drug-information/abstract-text/15284112/pubmed\" target=\"_blank\" id=\"15284112\">15284112</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16946304\"></a>Forstpointner R, Unterhalt M, Dreyling M, et al, &ldquo;Maintenance Therapy With Rituximab Leads to a Significant Prolongation of Response Duration After Salvage Therapy With a Combination of Rituximab, Fludarabine, Cyclophosphamide, and Mitoxantrone (R-FCM) in Patients With Recurring and Refractory Follicular and Mantle Cell Lymphomas: Results of a Prospective Randomized Study of the German Low Grade Lymphoma Study Group (GLSG),&rdquo; <i>Blood</i>, 2006, 108(13):4003-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fludarabine-drug-information/abstract-text/16946304/pubmed\" target=\"_blank\" id=\"16946304\">16946304</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gill S, Carney D, Ritchie D, et al, &ldquo;The Frequency, Manifestations, and Duration of Prolonged Cytopenias After First-Line Fludarabine Combination Therapy,&rdquo; <i>Ann Oncol</i>, 2010, 21(2):331-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fludarabine-drug-information/abstract-text/19625344/pubmed\" target=\"_blank\" id=\"19625344\">19625344</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Griggs JJ, Mangu PB, Anderson H, et al, &ldquo;Appropriate Chemotherapy Dosing For Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline,&rdquo;<i> J Clin Oncol</i>, 2012, 30(13):1553-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fludarabine-drug-information/abstract-text/22473167/pubmed\" target=\"_blank\" id=\"22473167\">22473167</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16344316\"></a>Hegenbart U, Niederwieser D, Sandmaier BM, et al. Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. <i>J Clin Oncol</i>. 2006;24(3):444-453.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fludarabine-drug-information/abstract-text/16344316/pubmed\" target=\"_blank\" id=\"16344316\">16344316</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Johnson SA, &ldquo;Clinical Pharmacokinetics of Nucleoside Analogues: Focus on Haematological Malignancies,&rdquo; <i>Clin Pharmacokinet</i>, 2000, 39(1):5-26.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fludarabine-drug-information/abstract-text/10926348/pubmed\" target=\"_blank\" id=\"10926348\">10926348</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Keating MJ, O'Brien S, Albitar M, et al, &ldquo;Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab as Initial Therapy for Chronic Lymphocytic Leukemia,&rdquo; <i>J Clin Oncol</i>, 2005, 23(18):4079-88.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fludarabine-drug-information/abstract-text/15767648/pubmed\" target=\"_blank\" id=\"15767648\">15767648</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18411419\"></a>Khouri IF, McLaughlin P, Saliba RM, et al, &ldquo;Eight-Year Experience With Allogeneic Stem Cell Transplantation for Relapsed Follicular Lymphoma After Nonmyeloablative Conditioning With Fludarabine, Cyclophosphamide, and Rituximab,&rdquo; <i>Blood</i>, 2008, 111(12):5530-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fludarabine-drug-information/abstract-text/18411419/pubmed\" target=\"_blank\" id=\"18411419\">18411419</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18000167\"></a>Lange BJ, Smith FO, Feusner J, et al, &ldquo;Outcomes in CCG-2961, a Children's Oncology Group Phase 3 Trial for Untreated Pediatric Acute Myeloid Leukemia: A Report From the Children's Oncology Group,&rdquo; <i>Blood</i>, 2008, 111(3):1044-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fludarabine-drug-information/abstract-text/18000167/pubmed\" target=\"_blank\" id=\"18000167\">18000167</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"11225999\"></a>McLaughlin P, Hagemeister FB, Rodriguez MA, et al, &ldquo;Safety of Fludarabine, Mitoxantrone, and Dexamethasone Combined With Rituximab in the Treatment of Stage IV Indolent Lymphoma,&rdquo; <i>Semin Oncol</i>, 2000, 27(6 Suppl 12):37-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fludarabine-drug-information/abstract-text/11225999/pubmed\" target=\"_blank\" id=\"11225999\">11225999</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"9625576\"></a>Montillo M, Mirto S, Petti MC, et al, &ldquo;Fludarabine, Cytarabine, and G-CSF (FLAG) for the Treatment of Poor Risk Acute Myeloid Leukemia,&rdquo; <i>Am J Hematol</i>, 1998, 58(2):105-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fludarabine-drug-information/abstract-text/9625576/pubmed\" target=\"_blank\" id=\"9625576\">9625576</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19528536\"></a>Pulsipher MA, Boucher KM, Wall D, et al, &ldquo;Reduced-Intensity Allogeneic Transplantation in Pediatric Patients Ineligible for Myeloablative Therapy: Results of the Pediatric Blood and Marrow Transplant Consortium Study ONC0313,&rdquo; <i>Blood</i>, 2009, 114(7):1429-36.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fludarabine-drug-information/abstract-text/19528536/pubmed\" target=\"_blank\" id=\"19528536\">19528536</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26429297\"></a>Rambaldi A, Grassi A, Masciulli A, et al. Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial. <i>Lancet Oncol</i>. 2015;16(15):1525-1536.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fludarabine-drug-information/abstract-text/26429297/pubmed\" target=\"_blank\" id=\"26429297\">26429297</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18056679\"></a>Rezvani AR, Storer B, Maris M, et al, &ldquo;Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation in Relapsed, Refractory, and Transformed Indolent Non-Hodgkin's Lymphoma,&rdquo; <i>J Clin Oncol</i>, 2008, 26(2):211-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fludarabine-drug-information/abstract-text/18056679/pubmed\" target=\"_blank\" id=\"18056679\">18056679</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Robak T, Dmoszynska A, Solal-C&eacute;ligny P, et al, &ldquo;Rituximab Plus Fludarabine and Cyclophosphamide Prolongs Progression-Free Survival Compared With Fludarabine and Cyclophosphamide Alone in Previously Treated Chronic Lymphocytic Leukemia,&rdquo; <i>J Clin Oncol</i>, 2010, 28(10):1756-65.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fludarabine-drug-information/abstract-text/20194844/pubmed\" target=\"_blank\" id=\"20194844\">20194844</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17503433\"></a>Sacchi S, Pozzi S, Marcheselli R, et al, &ldquo;Rituximab in Combination With Fludarabine and Cyclophosphamide in the Treatment of Patients With Recurrent Follicular Lymphoma,&rdquo;  <i>Cancer</i>, 2007, 110(1):121-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fludarabine-drug-information/abstract-text/17503433/pubmed\" target=\"_blank\" id=\"17503433\">17503433</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"14716342\"></a>Schetelig J, Bornhauser M, Kiehl M, et al, &ldquo;Reduced-Intensity Conditioning With Busulfan and Fludarabine With or Without Antithymocyte Globulin in HLA-Identical Sibling Transplantation - A Retrospective Analysis,&rdquo; <i>Bone Marrow Transplant</i>, 2004, 33(5):483-90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fludarabine-drug-information/abstract-text/14716342/pubmed\" target=\"_blank\" id=\"14716342\">14716342</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16314618\"></a>Tauro S, Craddock C, Peggs K, et al. Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. <i>J Clin Oncol</i>. 2005;23(36):9387-9393.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fludarabine-drug-information/abstract-text/16314618/pubmed\" target=\"_blank\" id=\"16314618\">16314618</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19015393\"></a>Treon SP, Branagan AR, Ioakimidis L, et al, &ldquo;Long-Term Outcomes to Fludarabine and Rituximab in Waldenstr&ouml;m Macroglobulinemia,&rdquo; <i>Blood</i>, 2009, 113(16):3673-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fludarabine-drug-information/abstract-text/19015393/pubmed\" target=\"_blank\" id=\"19015393\">19015393</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tsimberidou AM, McLaughlin P, Younes A, et al, &ldquo;Fludarabine, Mitoxantrone, Dexamethasone (FND) Compared With an Alternating Triple Therapy (ATT) Regimen in Patients With Stage IV Indolent Lymphoma,&rdquo; <i>Blood</i>, 2002, 100(13):4351-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fludarabine-drug-information/abstract-text/12393618/pubmed\" target=\"_blank\" id=\"12393618\">12393618</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"14675405\"></a>Virchis A, Koh M, Rankin P, et al, &ldquo;Fludarabine, Cytosine Arabinoside, Granulocyte-Colony Stimulating Factor With or Without Idarubicin in the Treatment of High Risk Acute Leukaemia of Myelodysplastic Syndromes,&rdquo; <i>Br J Haematol</i>, 2004, 124(1):26-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fludarabine-drug-information/abstract-text/14675405/pubmed\" target=\"_blank\" id=\"14675405\">14675405</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wierda W, O'Brien S, Wen S, et al, &ldquo;Chemoimmunotherapy With Fludarabine, Cyclophosphamide, and Rituximab for Relapsed and Refractory Chronic Lymphocytic Leukemia,&rdquo; <i>J Clin Oncol</i>, 2005, 23(18):4070-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fludarabine-drug-information/abstract-text/15767647/pubmed\" target=\"_blank\" id=\"15767647\">15767647</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8452 Version 184.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708775\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F171868\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F171869\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F171908\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F171872\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F171891\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F171873\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F171874\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15881449\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Obesity\" href=\"#F20344391\" class=\"outlineLink\">Dosing: Obesity</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F6853864\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F171848\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F171833\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F5950041\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F171851\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49132595\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F171849\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25725592\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F171916\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F171840\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F171854\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F171837\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299343\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F171842\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F171844\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F171856\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F5709863\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F171846\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F171836\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F171853\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323155\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F171857\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8452|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=fludarabine-patient-drug-information\" class=\"drug drug_patient\">Fludarabine: Patient drug information</a></li><li><a href=\"topic.htm?path=fludarabine-pediatric-drug-information\" class=\"drug drug_pediatric\">Fludarabine: Pediatric drug information</a></li></ul></div></div>","javascript":null}